Jürg Meier

Solvias AG engages in contract research, development, and manufacturing. It offers analytical, small molecule, biopharmaceutical, solid state development, catalysis technology, custom synthesis and manufacturing, and biological analysis services. The firm serves the pharmaceutical, biotech, medical devices, cosmetics, agro chemical, chemical, eletronic materials, and life sciences industries. The company was founded in 1999 and is headquartered in Kaiseraugst, Switzerland.

Part of JFG Life Sciences Stiftung der Universität Basel, Cardiolynx AG operates as a Swiss biotechnology company. The company is based in Basel, Switzerland.

Novartis Venture Fund provides early stage venture capital to companies in Europe, North America and Asia. The fund's focus is on the development of novel therapeutics and platforms, therefore it focuses on such sectors as Biotechnology and Biopharma. The fund makes seed and early stage investments ranging up to USD 30 million per company over its life. The fund makes follow-on and co-investments.

Part of Novartis AG, Biochemie GmbH is a manufacturer of drugs. The company is based in Kundl, Austria.

Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ.

Sandoz Pharmaceuticals AG develops and produces biopharmaceuticals. The firm specializes in the production of biopharmaceutical and biosimilars for the treatment and prevention of chronic diseases. It focuses on finding cure for diseases, such as cancer, multiple sclerosis, rheumatoid arthritis, and inherited metabolic disorders. The company was founded on January 6, 2006 and is headquartered in Rotkreuz, Switzerland.

Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada.